Friday, 21 Jul 2017

You are here

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. FDA has announced Arthritis Advisory Hearing on Aug 2nd (Sirukumab in RA) and Aug 3rd (Tofacitinib in PsA) http://buff.ly/2uiBRM7
  2. Metanalyses suggest a decreasing risk of CVD in rheumatoid arthritis after 2000 http://buff.ly/2vgC3Zu
  3. Monitoring IgG4 related disease w/ ESR CRP IgG4 levels not reliable. but imaging w/ 18F-FDG PET/CT reflects activity http://buff.ly/2tiFk9132
  4. SLE nephritis & 64 controls show pregnancy on lupus nephritis does not increase SLE flares, renal outcomes or CKD https://t.co/gK1lzJTZc9
  5. NEJM Study >73K shows Improved diet quality over 12 yrs associated w/ decreased risk of death (7-17% less mortality) https://t.co/2MOTfTiFPs
  6. Baricitinib gets market approval in Japan (https://t.co/9c0JmNMWjq) & NICE recommends Oluminant for UK approval (https://t.co/2Zchi0Kev3)
  7. IOM review shows uninsured have poorer health & shortened lives;Concludes health insurance reduces the risk of death https://t.co/0ndNNGzIoV
  8. Warnings section of the OTEZLA (apremilast) label updated to include risk of severe diarrhea, nausea, and vomiting. https://t.co/ljdKlcUlPbRT
  9. Population study of 40K Dutch finds ACPA positivity in 1%; assoc w/ age, smoking, female & RA;but only 15-20% had RA https://t.co/96DvKWPYTL
  10. increased pregnancy-induced type I IFN-inducible gene expression observed in preg RA women who improved during preg https://t.co/VwFrpH18YGRT
  11. Orencia Approved for Use in Psoriatic Arthritis  
  12. Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture
  13. Withdrawal of TNF Inibitors Fails in Most RA Patients
  14. Statins Improve Survival in Ankylosing Spondylitis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Jack-I may have mentioned this in the past but again wonder if the improvement of CVD in RA patients may be a result of the markedly decreased use of NSAIDs as background therapy in RA patients on cDMARDs and bDMARDs since 2000.-D,Knapp
I think yours is a very valid point as research has shown a definite decline in NSAID use after the VIOXX/Cox-2 FDA hearing. But are rheums using more low dose prednisone instead? Researchers should control for these issues in their analyses. Good Point! JC

More Like This

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

The RheumNow Week in Review – 30 June 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.

Highlights from EULAR 2017 - From RheumReports.com

Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017.